
    
      This was a single centre, open-label, randomised, 5-way crossover study design to compare the
      PK of Infacort® versus immediate-release hydrocortisone tablets and to evaluate the dose
      proportionality of 0.5 mg, 2 mg, 5 mg and 10 mg Infacort®. The study was conducted in 1
      cohort of 16 healthy male subjects and comprised a Screening Visit, 5 treatment periods
      (Treatment Periods 1 to 5) and a Post-study Visit.
    
  